A Phase 1/2a, dose-escalation study of FF-10501-01 for the treatment of advanced hematologic malignancies
This is a 2-part study. The goal of Part I of this clinical research study is to find the highest tolerable dose of FF-10501-01 that can be given to patients with refractory or relapsed MDS and/or CMML. The highest tolerable dose has been found and this part of the study is closed. The goal of Part II is to learn if the dose found in Part I can help to control MDS/CMML. The safety of this drug will also be studied.
Disease Group: Leukemia
Treatment Agent: FF-10501-01
Treatment Location: Both at MDACC & and Other Sites
Sponsor: FUJIFILM Pharmaceuticals U.S.A., Inc.
IRB Review and Approval Date: 07/11/2014
Recruitment Status: Open
Projected Accrual: 68
Information and next steps
Phase I/Phase II
For general questions about clinical trials: